🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

First reported case of coma from luminal breast cancer brain mets reversed without radiation: patient treated w/ nasogastric abemaciclib + fulvestrant post-surgery. Seizures resolved, imaging improved, full functional recovery—patient returned to work journals.sagepub.com/doi/epdf/10.11…

3 patients with metastatic KRAS-wildtype PDAC showed prolonged response to osimertinib after EGFR exon 19 deletion was found via NGS. Early molecular & metabolic responses seen; disease controlled for 6, 8, and 17 months. A case for rare mutation testing journals.sagepub.com/doi/epdf/10.11…

📊 In non-resectable stage III melanoma, T-VEC and IL-2 showed no significant differences in PFS (5.0 mo), OS (34.0 mo), or response rates. Both were well tolerated with minimal AEs. Real-world data to guide intralesional therapy choice. doi.org/10.1177/175883…

📌 In a Chinese LCNEC cohort (n=151), median OS was 17.8 mo. Adjuvant chemo post-surgery reduced distant spread & improved 2-yr OS (37.1% vs 79.9%, p<0.001). Immunochemotherapy outperformed chemo alone in advanced disease. doi.org/10.1177/175883…

In a cohort of 514 cancers, high ICOS expression (14%) was linked to elevated PD-1, PD-L1 & CTLA-4 RNA (all p<0.05) but not survival in ICI-treated or immunotherapy-naïve patients. Suggests ICOS ≠ prognostic, but may guide combo ICI strategies. doi.org/10.1177/175883…

In mRCC, second-line ICI vs TKI showed similar OS (44.8 vs 41.1 mo; p=0.446). But in NLR-high patients, TKI→ICI led to better survival vs TKI→TKI. Bone mets and nephrectomy history also influenced outcomes. 👉 NLR may guide 2L therapy: doi.org/10.1177/175883…

New real-world data from China compares flumatinib vs nilotinib as 1L treatment for chronic phase CML (n=165): 🔹 Similar MMR at 12 mo (85.1% vs 88.2%) 🔹 Nilotinib led to higher MR4 at all timepoints 🔹 Flumatinib had fewer metabolic/liver AEs 🔗 journals.sagepub.com/doi/epdf/10.11…

In real-world data from 147 advanced BTC patients refractory to gem/cis, second-line 5-FU-based therapy showed modest survival (median OS 4.8 mo). FOLFOX had comparable efficacy but better safety than Nal-IRI/FL or FOLFIRINOX—supporting role as 2L option. journals.sagepub.com/doi/epdf/10.11…

In NSCLC patients with bone metastases, those receiving palliative RT during ICI treatment had significantly better survival: median OS 16 mo vs 3 mo; PFS also improved. These findings support a synergistic role for RT with immunotherapy. 🔗 journals.sagepub.com/doi/epdf/10.11…